FASN and metabolic dysfunction-associated steatotic liver disease: Furthermore, itaconate, the enzymatic product of IRG1, ameliorates NAFLD progression by attenuating hepatic triglyceride deposition through direct inhibition of fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACC) activities [52].